Should I buy, hold, or sell EUDA stock right now?

EUDA Health Holdings Limited (EUDA) currently earns a Roarable Rating of D- (Sell — SELL) with 39/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is EUDA's 12-month price target and RQD AI Jury consensus?

EUDA's 12-month base price target is $16.19 (range $12.63 to $74.76), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / EUDA

ALPS (52) BMGL (53) PIII (24) NAKA (18) ⌘ Pro Terminal →

EUDA Health Holdings Limited (EUDA) — RQD Stock Rating Cockpit

$17.70 +14.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $18.12

EUDA Health Holdings Limited (EUDA) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $53.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EUDA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EUDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, EUDA Health Holdings Limited (NASDAQ: EUDA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $17.70 (+14.19% 1D, market cap $53.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, EUDA ranks #487 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EUDA compare to ALPS and BMGL in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), EUDA carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 43.9%, and ROIC of -35.0%. By comparison, ALPS (ALPS Group Inc Ordinary Share) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $54.1M) and BMGL (Basel Medical Group Ltd) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $68.5M). Among the 5-stock peer group, EUDA leads on earnings multiple (N/A) while NAKA leads on capital efficiency (-31.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EUDA?

▼

Per EUDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001847846), EUDA Health Holdings Limited generated $6.8M in revenue (+70.0% YoY), -$2.8M in net income, and -$2.5M in free cash flow against $1.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $18.12 (+2.36%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EUDA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY EUDA SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$17.01-12.4% Next Q

Q2 (-2Q)

Grade E$14.90-0.9% Next Q

Q3 (-1Q)

Grade E$14.76+19.9% Next Q

Current

Grade D-$17.70-7.6% Hist 90D α

Trajectory: E (31) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EUDA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EUDA currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.70) and Max Pain ($18.59) forces dealer call-delta covering toward $74.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EUDA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EUDA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

57.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE19% OF RANGE

L: $5$17.70H: $71

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on EUDA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 43.9% gross margin and -5.39% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (40)

14/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like EUDA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EUDA)

✓Walkthrough of EUDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EUDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.57%📐 WEDGE COMPRESSION COIL

2026-11-03O $15.50H $17.70L $15.50C $17.70VOL 35.6K

RES: $19.90SUP: $13.01SMA50: $15.70SMA200: $15.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EUDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EUDA Butterfly Map → + Track EUDA →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +70.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EUDA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EUDA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EUDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EUDA)

Health Care Rank #487 of 1015 ⚔️ ALPS vs EUDA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EUDA vs. ALPS, BMGL, PIII, NAKA)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, EUDA Health Holdings Limited (EUDA) ranks #487 by composite RQD confidence (39/100, grade D-) and #736 by equity capitalization ($53.0M). Within this direct 5-issuer industry benchmark cohort, EUDA leads on earnings valuation at N/A trailing P/E, while NAKA leads on capital efficiency and profitability with -31.6% ROIC and — gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with EUDA at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EUDA ACTIVE EUDA Health Holdings Limited	D-	39/100	—	43.9%	-35.0%	+14.19%	$53.0M	Benchmark Subject
ALPS ALPS Group Inc Ordinary Share	D+	52/100	—	—	—	+0.03%	$54.1M	/alps-vs-euda →
BMGL Basel Medical Group Ltd	D+	53/100	—	—	—	+6.11%	$68.5M	/bmgl-vs-euda →
PIII P3 Health Partners Inc. (Class A)	E	24/100	—	—	-35.0%	-4.05%	$29.3M	/piii-vs-euda →
NAKA Nakamoto Inc.	E	18/100	—	—	-31.6%	-14.83%	$107.5M	/naka-vs-euda →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001847846 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), EUDA Health Holdings Limited (EUDA) reported GAAP revenue of $6.8M (+70.0% vs. FY2024 revenue of $4.0M , and +84.0% cumulative change since FY2023) , GAAP net income of -$2.8M, operating cash flow of -$2.4M, and free cash flow of -$2.5M (-17.5% YoY). On the balance sheet, EUDA closed FY2025 with $1.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.8M	-$2.8M	-$2.4M	-$2.5M	$1.7M	—
FY2024 (FY)	2024-12-31	$4.0M	-$15.4M	-$2.0M	-$2.1M	$1.7M	—
FY2023 (FY)	2023-12-31	$3.7M	-$10.0M	-$2.9M	-$2.9M	—	—

3. EUDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EUDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EUDA compare to ALPS and BMGL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EUDA?

Where is EUDA trading relative to its 50-day, 200-day, and 52-week technical levels?

EUDA last traded at $17.70 (+14.19% on volume of 35,623 shares), positioning the stock +12.74% above its 50-day simple moving average ($15.70) and +16.14% above its 200-day simple moving average ($15.24). Across its 52-week range of $5.26 to $71.20, EUDA sits at the 18.9% percentile with a 14-day RSI of 57.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($15.49 to $19.91).

Direct Sub-Reports: EUDA RQD Cockpit EUDA 12M Forecast EUDA Earnings & Move EUDA Dividends & DRIP EUDA Insiders & 13F EUDA Whale Options EUDA Profit Sankey EUDA News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ SEC XBRL & RQD VERIFIED

EUDA — EUDA Health Holdings Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

EUDA Health Holdings Limited (EUDA) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $17.70 (+14.19% 1D, market capitalization $53.0M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 43.9%, operating margin of -36.3%, and free cash flow yield of -5.39%.
Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

EUDA Health Holdings Limited is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Nursing Services industry, per the SEC profile. Reported revenue of $6.8M for FY 2025 indicates an operating business with a commercial revenue base, . The gross margin of 43.9% per the market data suggests the company retains a portion of revenue after direct costs.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), EUDA Health Holdings Limited (EUDA) reported $6.8M in annual revenue (up from $4.0M in FY2024, +70.0% YoY) and -$2.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.7M revenue, -$10.0M net income) through FY2025, EUDA scaled operating cash flow to -$2.4M and free cash flow to -$2.5M, backed by $1.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -5.39% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $5.26 – $71.20 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -36.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data.

Key Question #1: Can EUDA sustain or expand its -36.3% operating margin and -35.0% ROIC against Medical/Nursing Services peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $6.8M and free cash flow of -$2.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is EUDA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

EUDA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for EUDA Health Holdings Limited (EUDA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EUDA Debate Forum (3) ↓

🟡 MARKET WIRE Benzinga • 4d ago

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 155d ago

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 155d ago

EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Singapore, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, received a w

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 189d ago

EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

SINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and Chin

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 190d ago

EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities

Singapore, April 27, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasd

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 69d ago

EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore

SINGAPORE, AUGUST, Aug. 26, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based distributor of third-party wellness and non-invasive healthcare products and s

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 96d ago

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

SINGAPORE, July 30, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a fo

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 98d ago

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a fo

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EUDA Bull vs. Bear Conversation Board — What's Your Call at $17.70?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EUDA 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $20.71 (+17.0%)

📌 Pinned Debate

Revenue grew from $3.7M in FY 2023 to $6.8M in FY 2025 while operating losses narrowed from -$17.3M to -$2.5M.

The street is overcomplicating EUDA Health Holdings Limited (EUDA). Revenue grew from $3.7M in FY 2023 to $6.8M in FY 2025 while operating losses narrowed from -$17.3M to -$2.5M.. With an RQD score of 39/100 (D-) and Forensic Balance Sheet at 11/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $19.12.

ArenaChamp_24 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Nursing Services. If gross margin (43.9%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $15.04 (-15.0%)

Spot @ $17.70

ROIC of -35% and an FCF yield of -5.39% show the operating model is not yet generating returns or free cash flow.

ROIC of -35% and an FCF yield of -5.39% show the operating model is not yet generating returns or free cash flow.. Look at the math on EUDA: paying current EV/EBITDA multiples for -35.0% ROIC and -36.3% operating margins leaves zero margin of safety if Medical/Nursing Services demand softens. I'd wait for a retest of $15.58 before getting long.